Programme Thesis
Concours i-Lab 2026 is a French deep-tech competition operated by Bpifrance under France 2030, providing non-dilutive grants up to €600K to early-stage innovators and startups (under 2 years) with strong R&D foundations. It exists to accelerate the creation and growth of technology-intensive ventures in France, fostering national champions in sectors like health, AI, and biotech.
Selection Criteria
- Innovation and maturity of proof-of-concept (technical feasibility, TRL level)
- Economic viability and business model (market size, revenue model, go-to-market strategy)
- Growth potential in France and internationally (scalability, exportability)
- Quality and commitment of the founding team (relevant expertise, full-time dedication)
- Applicant's ability to lead the project and build partnerships (industry, academic, ecosystem)
- Intellectual property strategy (patents, freedom-to-operate, licensing)
- Environmental and societal impacts (positive externalities, sustainability integration)
- Budget coherence and alignment with R&D plan (eligible expenses up to €1M, max €600K grant)
Past Winners / Cohort Profiles
Past i-Lab winners typically include deep-tech startups in health (e.g., biotech, medtech), AI, robotics, and greentech, often spun out from French public research labs (CNRS, INSERM, CEA). Archetypes: a team of 2-4 co-founders with a mix of scientific and business backgrounds, holding a patent or provisional patent, with a validated prototype or pre-clinical data. Named examples from previous years include Therapixel (AI radiology), Poietis (bioprinting), and Energysquare (wireless charging), though specific 2026 winners are not listed on the page.
Ideal Candidate Fingerprint
The platonic ideal applicant is a French-resident or France-based entrepreneur (or team) with a deep-tech innovation at TRL 4-6, holding a patent or provisional patent, with a clear business plan targeting a global market. They have strong academic or industry partnerships in France, a committed founding team with complementary skills, and a compelling societal impact story, especially in health or sustainability.
Recommended Framing
Eniola should position the CCT model as a deep-tech AI-biotech platform with validated pre-clinical data (85.8% encoding reduction) and a provisional patent, emphasizing its potential to revolutionize addiction treatment globally. Leverage the existing collaborations with Servier and Paris-Saclay to demonstrate strong French ecosystem integration, and frame the venture as a France-based spin-off (e.g., ZYCO France) that addresses a major societal burden (addiction) with a scalable, IP-protected solution. Highlight Eniola's unique profile as an independent Nigerian researcher with top-tier endorsements (Berridge, Gershman) to show international credibility and diversity, aligning with i-Lab's openness to non-French founders.
Watch Out
Eniola is not currently based in France and must demonstrate a credible plan to create a company in France (e.g., via a French co-founder, incubator affiliation, or relocation). The programme requires the company to be created or less than 2 years old; Eniola has no existing French entity, so the application must be as a 'future creator' with a clear timeline for incorporation. Additionally, the deadline (3 Feb 2026) is very tight for assembling a full business plan, budget, and team; Eniola may need to secure a French co-founder or incubator partner quickly.